Six Degrees of Separation: the Oxygen Effect in the Development of Radiosensitizers

Overview

Journal Transl Oncol

Specialty Oncology

Date 2011 Aug 2

PMID 21804913

Citations 37

Authors

Bryan T Oronsky

Susan J Knox

Jan Scicinski

Affiliations

Soon will be listed here.

Abstract

The popular theory six degrees of separation is used in this review as an analogy to relate all radiosensitization to oxygen. As the prime mover of all radiosensitizers, the pervasive influence of oxygen has consciously or unconsciously influenced the direction of research and development and provided the benchmark against which all other compounds and approaches are measured. It is the aim of this review to develop the six degrees of separation from oxygen analogy as a unifying framework for conceptually organizing the field and for giving context to its varied subspecializations and theories. Under such a framework, it would become possible for one area to consider questions and problems found in other areas of radiosensitization, using a common analogy, that would allow for further development and unification of this multifaceted discipline. In this review, approaches to the development of radiosensitizers and the current state of research in this field are discussed, including promising new agents in various stages of clinical development.

Citing Articles

Exploring the molecular mechanism of cancer radiosensitization: the impact of physical stimulation therapy.

Liu S, Li M, Guo Z, Chen Z Strahlenther Onkol. 2025; .

PMID: 40067453 DOI: 10.1007/s00066-025-02385-0.

Modeling of chemo-radiotherapy targeting growing vascular tumors: A continuum-level approach.

Lampropoulos I, Koutsi M, Kavousanakis M PLoS One. 2025; 20(1):e0301657.

PMID: 39813216 PMC: 11734981. DOI: 10.1371/journal.pone.0301657.

Golden era of radiosensitizers.

cizkova J, Dolezal O, Buchta V, Pospichal J, Blanar V, Sinkorova Z Front Vet Sci. 2024; 11:1450776.

PMID: 39711799 PMC: 11659289. DOI: 10.3389/fvets.2024.1450776.

Asymmetrically PEGylated and amphipathic heptamethine indocyanine dyes potentiate radiotherapy of renal cell carcinoma via mitochondrial targeting.

Wu Z, Huang X, Wu C, Zhou Y, Gao M, Luo S J Nanobiotechnology. 2024; 22(1):756.

PMID: 39695771 PMC: 11658457. DOI: 10.1186/s12951-024-03012-3.

STING agonist-conjugated metal-organic framework induces artificial leukocytoid structures and immune hotspots for systemic antitumor responses.

Luo T, Jiang X, Fan Y, Yuan E, Li J, Tillman L Natl Sci Rev. 2024; 11(7):nwae167.

PMID: 38887543 PMC: 11182667. DOI: 10.1093/nsr/nwae167.

References

Iyer V, SZYBALSKI W . MITOMYCINS AND PORFIROMYCIN: CHEMICAL MECHANISM OF ACTIVATION AND CROSS-LINKING OF DNA. Science. 1964; 145(3627):55-8. DOI: 10.1126/science.145.3627.55. View

Zeman E, Brown J, Lemmon M, Hirst V, Lee W . SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys. 1986; 12(7):1239-42. DOI: 10.1016/0360-3016(86)90267-1. View

Schellens J, Planting A, van Acker B, Loos W, de Boer-Dennert M, van der Burg M . Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. J Natl Cancer Inst. 1994; 86(12):906-12. DOI: 10.1093/jnci/86.12.906. View

Schwartz D, Bankson J, Lemos Jr R, Lai S, Thittai A, He Y . Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther. 2010; 9(7):2057-67. PMC: 2935253. DOI: 10.1158/1535-7163.MCT-09-0768. View

Tamm I, Wang Y, Sausville E, Scudiero D, Vigna N, Oltersdorf T . IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998; 58(23):5315-20. View

Frederiksen L, Sullivan R, Maxwell L, Macdonald-Goodfellow S, Adams M, Bennett B . Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling. Clin Cancer Res. 2007; 13(7):2199-206. DOI: 10.1158/1078-0432.CCR-06-1807. View

Rao D, Mason R . Generation of nitro radical anions of some 5-nitrofurans, 2- and 5-nitroimidazoles by norepinephrine, dopamine, and serotonin. A possible mechanism for neurotoxicity caused by nitroheterocyclic drugs. J Biol Chem. 1987; 262(24):11731-6. View

Patterson L, McKeown S . AQ4N: a new approach to hypoxia-activated cancer chemotherapy. Br J Cancer. 2000; 83(12):1589-93. PMC: 2363465. DOI: 10.1054/bjoc.2000.1564. View

Brown J, Lemmon M . Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int J Radiat Oncol Biol Phys. 1991; 20(3):457-61. DOI: 10.1016/0360-3016(91)90057-b. View

10.

Isenberg J, Romeo M, Abu-Asab M, Tsokos M, Oldenborg A, Pappan L . Increasing survival of ischemic tissue by targeting CD47. Circ Res. 2007; 100(5):712-20. DOI: 10.1161/01.RES.0000259579.35787.4e. View

11.

Mayer R, Hamilton-Farrell M, van der Kleij A, Schmutz J, Granstrom G, Sicko Z . Hyperbaric oxygen and radiotherapy. Strahlenther Onkol. 2005; 181(2):113-23. DOI: 10.1007/s00066-005-1277-y. View

12.

Brown J . SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer. 1993; 67(6):1163-70. PMC: 1968495. DOI: 10.1038/bjc.1993.220. View

13.

Dasu A, Denekamp J . New insights into factors influencing the clinically relevant oxygen enhancement ratio. Radiother Oncol. 1998; 46(3):269-77. DOI: 10.1016/s0167-8140(97)00185-0. View

14.

Kostova I . Lanthanides as anticancer agents. Curr Med Chem Anticancer Agents. 2005; 5(6):591-602. DOI: 10.2174/156801105774574694. View

15.

Wang G, Semenza G . General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A. 1993; 90(9):4304-8. PMC: 46495. DOI: 10.1073/pnas.90.9.4304. View

16.

Ahmed A, Loes D, Bressler E . Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy. Neurology. 1995; 45(3 Pt 1):588-9. DOI: 10.1212/wnl.45.3.588. View

17.

Nishida C, de Montellano P . Reductive heme-dependent activation of the n-oxide prodrug AQ4N by nitric oxide synthase. J Med Chem. 2008; 51(16):5118-20. PMC: 2730118. DOI: 10.1021/jm800496s. View

18.

Bonavida B, Khineche S, Huerta-Yepez S, Garban H . Therapeutic potential of nitric oxide in cancer. Drug Resist Updat. 2006; 9(3):157-73. DOI: 10.1016/j.drup.2006.05.003. View

19.

Palayoor S, Mitchell J, Cerna D, DeGraff W, John-Aryankalayil M, Coleman C . PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells. Int J Cancer. 2008; 123(10):2430-7. PMC: 4277812. DOI: 10.1002/ijc.23807. View

20.

Siim B, Atwell G, Anderson R, Wardman P, Pullen S, Wilson W . Hypoxia-selective antitumor agents. 15. Modification of rate of nitroreduction and extent of lysosomal uptake by polysubstitution of 4-(alkylamino)-5-nitroquinoline bioreductive drugs. J Med Chem. 1997; 40(9):1381-90. DOI: 10.1021/jm9607865. View